No headlines found.
No press releases found.
No news found.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
Curanex Pharmaceuticals trades on the NASDAQ stock market under the symbol CURX.
As of February 11, 2026, CURX stock price declined to $0.29 with 133,972 million shares trading.
CURX has a beta of 0.79, meaning it tends to be less sensitive to market movements. CURX has a correlation of 0.00 to the broad based SPY ETF.
CURX has a market cap of $8.21 million. This is considered a Sub-Micro Cap stock.
CURX support price is $.28 and resistance is $.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CURX shares will trade within this expected range on the day.
